Appointment of Joint Broker

Hutchison China Meditech Limited
05 January 2007


                                                                  5 January 2007

            Hutchison China MediTech Limited ('Chi-Med') (AIM: HCM)

                          Appointment of Joint Broker

London: Friday, 5 January 2007: Chi-Med today announces that it has appointed
Investec Bank (UK) Limited as its Joint Broker effective on 5 January 2007.
Panmure Gordon (Broking) Limited will continue to act as a broker to Chi-Med.

                                      Ends

Enquiries

Chi-Med                           Telephone: [phone]
Christian Hogg, CEO

Citigate Dewe Rogerson            Telephone: [phone]
Anthony Carlisle                  [phone]
Chris Gardner                     [phone]
Yvonne Alexander                  [phone]

Notes to Editors

Chi-Med is the holding company of a pharmaceutical and healthcare group based
primarily in China and was admitted to trading on the Alternative Investment
Market of the London Stock Exchange in May 2006. Chi-Med is focused on
researching, developing, manufacturing, and selling pharmaceuticals, health
supplements and other consumer health and personal care products derived from
Traditional Chinese Medicine and botanical ingredients. Its overall aim is to
draw on the untapped wealth of knowledge and history of usage in the Traditional
Chinese Medicine industry to develop products for the global market. The Company
has three complementary businesses: drug R&D, China healthcare and consumer
products.

Hutchison MediPharma is Chi-Med's wholly-owned drug research and development
company and has a team of around 100 scientists and staff focusing on botanical
drugs, semi-synthetic natural product drugs, and synthetic single chemical
entity drugs. It currently has two candidates in clinical development in both
the US and China. HMPL-002, a radiosensitiser for head and neck and non-small
cell lung cancer ('NSCLC'), is in Phase I/II in the US and in proof of concept
in China. HMPL-004, an inhibitor to a group of inflammatory cytokines, for
treatment of inflammatory bowel diseases ('IBD'), including Crohn's Disease
('CD') and Ulcerative Colitis ('UC'), is in Phase II in the US and in proof of
concept in China. Hutchison MediPharma also has a pipeline of single molecular
entity discovery projects in the auto-immune/inflammatory diseases and oncology
therapeutic areas which have shown activity against clinically validated
targets.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international
corporation listed on the Main Board of The Stock Exchange of Hong Kong Limted.



                      This information is provided by RNS
            The company news service from the London Stock Exchange
 END
MSCMGGGMZDNGNZM